$APRE
Aprea Therapeutics, Inc. Common stock
XNAS
Why is APRE up today? It is at $0.800 (+24.94%), and our scanner flagged it 12 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment APRE spikes, and full due diligence on APRE — key stats, earnings, dilution and insider activity. Free.
Get free $APRE alerts the moment volume spikes
Our scanner flagged $APRE 12 times in the last 30 days. Create a free account to track $APRE, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $0.800
- Change today
- +24.94%
- Previous close
- $0.640
- 52-week range
- $0.548 – $1.69
- Market cap
- $8M
- Institutional own.
- 19.29%
- Total held
- 30.0%
- Tradeable float
- 8.8M 70% of shares · after 11% insiders + 19% institutions
- Short interest
- 41K ▼ -32% vs prior · as of 2026-07-31
- Short % of float
- 0.5%
- Days to cover
- 1.0d
- Avg daily volume
- 653K
- Exchange
- XNAS
- 5mthin
- 4.0x
- 15mthin
- 1.2x
- 1hthin
- 0.8x
- 1D
- 20x
Get free APRE + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $APRE up today?
APRE is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on APRE today, peaking at 877.5x its normal volume. A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystAprea Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13G/APassive 5%+ stake updatedAug 13, 2026 · 11 days agoInsiders
Insiders buying2 open-market buys8 buys, 0 sells last 3 months (14/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Seizinger Bernd R. Director | Acquired (grant/award) | +3K 0.02% of company | added 6.8% | 49K | n/a | Jun 16, 26 |
Pamukcu Rifat Director | Acquired (grant/award) | +3K 0.02% of company | added 58% | 9K | n/a | Jun 16, 26 |
Duey Marc Director | Acquired (grant/award) | +3K 0.02% of company | added 1.2% | 259K | n/a | Jun 16, 26 |
Bizzari Jean-Pierre Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 4K | n/a | Jun 16, 26 |
Henneman John B Iii Director | Acquired (grant/award) | +3K 0.02% of company | added 31% | 13K | n/a | Jun 16, 26 |
Peters Richard Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 6K | n/a | Jun 16, 26 |
Gruia Gabriela Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 4K | n/a | Jun 16, 26 |
Grissinger Michael Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 6K | n/a | Jun 16, 26 |
Hamill John P. Officer | Acquired (grant/award) | +10K 0.08% of company | added 30% | 44K | n/a | Mar 12, 26 |
Gilad Oren Officer | Acquired (grant/award) | +20K 0.2% of company | added 5.4% | 394K | n/a | Mar 12, 26 |
Hamill John P. Officer | Bought (open market) | +6K 0.05% of company | added 21% | 33K | $5K at $0.890 | Jan 30, 26 |
Gilad Oren Officer | Bought (open market) | +28K 0.2% of company | added 8.1% | 374K | $25K at $0.890 | Jan 30, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $APRE runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 23,696,047 new shares
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$APRE Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$APRE Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
APRE stock FAQ
Why is $APRE up today?
APRE is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on APRE today, peaking at 877.5x its normal volume. A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
What is the APRE stock price today?
APRE last traded at $0.800, up 24.94% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live APRE alerts?
The APRE Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged APRE 12 times in the last 30 days.
What exchange is APRE on?
APRE (Aprea Therapeutics, Inc. Common stock) trades on XNAS, with a market cap of about $8M.
Is APRE good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge APRE for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.